ETH Zürich Jahresbericht 2014; Januar / Februar 2015; Mattias Ivarsson hat ein Molekül entwickelt, das einen der häufigsten Krankenhauskeime, das Bakterium Clostridium difficile, bekämpft. Von der ETH Zürich erhielt er dafür ein Pioneer Fellowship: Mit diesem Stipendium unterstützt die Hochschule junge Forschende bei der Entwicklung innovativer Produkte und Dienstleistungen. Das neu entwickelte Molekül wurde bereits erfolgreich getestet und patentiert.; Mattias Ivarsson has developed a molecule which combats one of the most common hospital bugs, the bacterium Clostridium difficile. For his work in this area, ETH Zurich has awarded him a Pioneer Fellowship: a grant which the university offers to support young researchers in developing innovative products or services. The new molecule has already been tested successfully and patented.
Categories
Most Recent
- Preclinical work on INS-3001 efficacy in renal fibrosis published
- Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
- Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
- Preclinical work on calcium oxalate inhibitors for renal indications published
- Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications